Stock AnalizOpko Health, Inc. OPK
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Opko Health, Inc. (OPK) is a healthcare company listed in the US with a market value of about $1.2B. In the twelve months to September 30, 2026 it had revenue of $654M and net income of -$148M, a net margin of -22.6%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -16% a year, a 5-year average ROIC of -6%.
Score: 0.8 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $654M | $607M | $713M | $863M | $1.0B | $1.8B | $1.4B | $902M | $990M | $1.1B | $1.2B |
| Net income | -$148M | -$226M | -$53M | -$189M | -$328M | -$30M | $31M | -$315M | -$153M | -$305M | -$48M |
| Free cash flow | -$135M | -$191M | -$208M | -$44M | -$120M | $6M | $6M | -$185M | -$137M | -$139M | $13M |
| EPS (diluted) | $-0.19 | $-0.30 | $-0.08 | $-0.25 | $-0.46 | $-0.05 | $0.05 | $-0.53 | $-0.27 | $-0.55 | $-0.10 |
| Net margin | -22.6% | -37.2% | -7.5% | -21.9% | -32.7% | -1.7% | 2.1% | -34.9% | -15.4% | -28.6% | -4.0% |
| ROIC | — | -6.6% | -6.4% | -8.5% | -10.2% | 0.8% | 1.9% | -11.2% | -7.4% | -11.8% | -3.7% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 5 analysts is $4.15, 147% above the current price; targets range from $2.25 to $8.50; the consensus rating is “Buy”; expected EPS is $-0.24 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Opko Health pay a dividend?
Not currently.
Is Opko Health a good stock to buy?
We do not give buy or sell advice. Opko Health scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.